Momotanijuntenkan Ltd

Skin Medical Research

It is our mission to create and provide products and services that realize our corporate philosophy: "We contribute to the well-being of people by helping them achieve beautiful skin and thereby enriching their mind." To move ahead with this mission, we work in collaboration with medical institutions, for example, when we promote research to prevent and relieve skin problems caused by drugs. We seek to enhance to enhance the quality of life (QOL) of patients in cooperation with medical institutions.


Elucidation of the pathogenic mechanism of skin problems caused by molecular target therapies of cancer and research and development of a drug to prevent and relieve the skin problems

Cancer chemotherapy has been making rapid progress with the advent of molecular target agents. Initially, molecular target therapy was believed to have few side effects. However, it has become a major cause of lowering the QOL of patients during therapy because it is now clear that molecular target therapy causes much more serious side effects, which can affect cancer treatment, than first thought. At present, there is no method to prevent or relieve skin problems based on the onset mechanism of the skin problems. It cannot be said that cancer treatments based on the existing empirical rules have brought about good results.

Masajiro Momotani, who was born to a family operating a pharmacy, opened a new chapter in his life by creating "BIGANSUI Acne Lotion" for his wife, who suffered acne. He started the business of manufacturing commercial drugs under the trade name "Momotanijuntenkan." Backed by its long history and under the corporate philosophy of "contributing to the well-being of people by helping them achieve beautiful skin and thereby enriching their mind," Momotanijuntenkan is endeavoring to implement and promote research in collaboration with medical institutions.

Research paper presentation

November 2021 The Oncologist(In press) Safety and Efficacy of Bis-Glyceryl Ascorbate as Prophylaxis for Hand-Foot Skin Reaction: A Single-Arm, Open-Label Phase I/II study (DGA study)
March 2021 Experimental Dermatology Vol.30 No.3 p337-346, 2021 Sunitinib decreases the expression of KRT6A and SERPINB1 in 3D human epidermal models
August 2019 Journal of Medical Internet Research (JMIR) Research Protocols. Vol. 8 No.8, e14636, 2019 Safety and Efficacy of Bis-Glyceryl Ascorbate (Amitose DGA) to Prevent Hand-Foot Skin Reaction in Patients With Renal Cell Carcinoma Receiving Sunitinib Therapy: Protocol for a Phase I/II, Uncontrolled, Single-Arm, Open-Label Trial.
September 2017 Biological & Pharmaceutical Bulletin (BPB) Vol.40 No.9 P1530-1536, 2017 Effects of Ascorbyl-2-Phosphate Magnesium on Human Keratinocyte Toxicity and Pathological Changes by Sorafenib
Conference presentation
March 2020 The 140th Annual Meeting of the Pharmaceutical Society of Japan Sunitinib-induced expression changes of keratin 6A and SERPINB1 in human keratinocytes
July 2018 The 18th World Congress of Basic and Clinical Pharmacology (WCP2018) Effects of sunitinib on the expression of keratin 9 in human keratinocyte cell lines and a 3D skin model
September 2017 The 15th International Congress of Therapeutic Drug Monitoring & Clinical Toxicology (IATDMCT 2017) Bench-to-bedside research for the dermatological side effects induced by multiple tyrosine kinase inhibitors
Molecular cornifying mechanisms of multi-targeted tyrosine kinase inhibitorsinduced
hand-foot skin reaction based on genetic differences of STAT3

Publication of information on specified clinical trials

* An example of research has been provided.